Atlas Growers Denmark A/S has received its licences to begin cultivation from the Danish Medicine Agency:
Authorization has been granted for initial cannabis production of the newly acquired 170,000 sq. ft. facility located on Funen, Denmark which will serve as Atlas’ European base of operations. The cultivation license allows Atlas to import starting materials and begin propagation and development of medical cannabis-based products. "Under the Danish Medicines Agency’s Development Scheme, the initial license permits the receipt, possession, and processing of cannabis, as well as distribution and export of analytical samples," the team with the company explains. "The first harvest is scheduled for early 2020. After three confirmed homogeneous crops, an additional license will be issued allowing for the sale of authorized medicinal cannabis products." Atlas plans to use this production facility to supply its secured sale contracts in the rest of the European Union, while also supplying Nordic countries.
"The property features 36 individual climate-controlled rooms, allowing for in-house cultivation of pharmaceutical-grade cannabis flowers," they further explain. "New construction of an onsite 20,000 sq. ft. GMP laboratory will allow for production of pure, extracted medical inputs, & pharmaceutical manufacturing of down-stream finished goods. Like in Canada, individual microclimates can be tailored to the unique environmental demands of each specific medical cannabis cultivar, or plant variety." Atlas intends to create over 100 new jobs within the region.
Sheldon Croome, Atlas President & CEO notes: “We are thankful to the Danish Medicines Agency for the issuance of this valuable license, which allows Atlas to begin production of medical cannabis in Denmark.”
Kent Stenvang, Atlas Growers Denmark A/S Vice President added: “This license further solidifies Atlas’ position in the European market and ensures we will be able to meet the demand of our buyers worldwide. Our exciting clinical initiatives with prestigious post-secondary institutions aim to create clinical proof for our products, which in turn will give physicians the confidence they need to prescribe cannabis products. Our aim is that this will allow patients across Europe to have better access to our sought-after products.”